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Purpose:Older patients with head and neck cancer (HNC) represent a challenging group,
as frailty and comorbidities need to be considered. This study aimed to evaluate the
efficacy and side effects of curative and palliative (chemo) radiation ([C]RT) with regard to
basic geriatric screening in older patients.
Methods: This study included HNC patients aged ≥70 years who were treated with
curative or palliative (C)RT. Clinicopathological data including Charlson Comorbidity Index
(CCI), Karnofsky performance status (KPS), and treatment data were analyzed as
predictors of overall survival (OS).
Results: A total of 271 patients (median age, 74 years) were enrolled. The majority had
UICC stage III/IV (90%) and underwent curative treatment (85.2%). A total of 144 (53.1%)
patients received definitive and 87 (32.1%) had adjuvant (C)RT. Overall, 40 patients
(14.8%) received palliative (C)RT. Median follow-up duration (curative setting) was 87
months, and the 2- and 5-year OS rates were 57.8 and 35.9%, respectively. Median OS
was significantly different for age ≤75 vs. >75 years, CCI <6 vs. ≥6, KPS ≥70 vs. <70%,
Tx/T1/T2 vs. T3/T4, and adjuvant vs. definitive (C)RT, respectively. Age 70–75 years (p =
0.004), fewer comorbidities when CCI < 6 (p = 0.014), good KPS ≥ 70% (p = 0.001), andFebruary 2021 | Volume 10 | Article 5663181
Stromberger et al. Radiotherapy for Older HNC Patients
Frontiers in Oncology | www.frontiersin.orgadjuvant (C)RT (p = 0.008) independently predicted longer survival. Palliative RT resulted
in a median OS of 4 months.
Conclusion: Older age, lower KPS, higher CCI, and definitive (C)RT are indicators of
worse survival in older patients with HNC treated curatively. Without a comprehensive
geriatric assessment in patients aged >75 years, the KPS and CCI can be useful tools to
account for “fitness, vulnerability or frailty” to help in treatment decision-making.Keywords: head and neck cancer (HNC), head and neck squamous cell carcinoma (HNSCC), older patients, head
and neck cancer, survival, chemoradiation, volumetric modulated arc therapy (VMAT), radiationINTRODUCTION
In developed countries, older generations are becoming the
dominant demographic groups, and the number of oncological
patients is increasing. In addition, the number of deaths among
cancer patients aged 80 years and older is almost twice as often
as from heart disease than from cancer (1). How to deal with
older oncological patients? The question being frequently asked
by oncologists, surgeons, and radiation oncologists in recent
years. Worldwide, head and neck cancer (HNC) cases account
for approximately 650,000 cases annually (1). In Europe, it
accounts for an estimated 4% of all cancer incidences (2).
Curative treatment of locally advanced (LA) HNC with
surgery and/or chemoradiation (CRT) is commonly
associated with severe treatment-related toxicity, and recent
findings suggest that older patients >70 years with locally
advanced head and neck squamous cell carcinoma (HNSCC)
have an increased 90-day mortality after concurrent CRT (3).
Furthermore, older patients with HNC have a 1-year mortality
rate of 42.3%, and malnutrition and immobility seem to be
independent negative predictors for worse survival (4). In
addition, HNC patients aged ≥70 years are under-represented
in prospective randomized trials. With limited data on older
patients, as only approximately 7.5% of patients were aged 71
years or older, a meta-analysis showed that the estimated
survival benefit of approximately 6.5% at 5 years with
simultaneous platinum-based CRT for LA HNC patients
significantly disappeared with increasing age (p = 0.003) (5).
Some recommendations for screening tools in the geriatric
assessment of older patients with cancer are available (6, 7).
However, in daily oncological practice in many countries, a
comprehensive geriatric assessment (CGA) is seldom part of
the decision-making process in a multidisciplinary approach
for older patients with HNC. The selection of older patients
fit for an intensive multimodal treatment or moderately suitable
for less intensive curative radiotherapy alone (RT), and frail
older patients appropriate for palliative RT or best supportive
care needs careful evaluation to achieve the greatest benefit for
the individual patient.
The aim of this study was to evaluate the “treatment decision”
made by an interdisciplinary team in terms of outcome and
predictive factors for survival in older patients with HNC treated
with curative or palliative (chemo)radiation (C)RT based on
comorbidities and performance status.2
MATERIALS AND METHODS
Study Design and Setting
After receiving institutional review board approval (EA2/140/19),
data from all older patients (age ≥ 70 years) with histologically
confirmed head and neck malignancies (oro-/hypo-/nasopharynx,
oral cavity, larynx nasal/paranasal sinuses, salivary glands, cancer
of unknown primary (CUP) treated at the Department of
Radiation Oncology, Charité–Universitätsmedizin Berlin,
between January 2005 and October 2015 were reviewed. Tumor
stage, nodal stage, UICC stage (7th edition TNM classification),
Karnofsky performance status (KPS), Charlson Comorbidity
Index (CCI), curative definitive, and adjuvant (C)RT with
resection margin (R0, R1 or close <5 mm) and/or extranodal
extension (ENE), palliative RT, RT technique, and total RT dose
were analyzed retrospectively from electronic and paper charts.
Comorbidity conditions were evaluated with the use of the CCI,
the sum of a point-based scoring system based on 19 pathologic
conditions (8). A web-based tool for the prediction of age-adjusted
10-year survival in patients with multiple comorbidities was used
to calculate CCI (9). Acute treatment-related toxicity was scored
according to Common Terminology Criteria for Adverse Events
(CTCAE) Version 4.0 (10).
Follow-Up and Survival
All patients had follow-up examinations scheduled at three
months post treatment and 6-monthly thereafter for the first
five years. Physical examination and yearly computed
tomography (CT) or magnetic resonance imaging of the head
and neck region, thorax, and abdomen were part of the follow-
up. Overall survival (OS) was calculated from the beginning of
the (C)RT until the last follow-up or death from any cause. In
addition, survival data were collected from the tumor registry
(Gießener Tumordokumentationssystem, GTDS) and the
Charité Comprehensive Cancer Center.
Statistical Analysis
Descriptive statistics of patient baseline and tumor characteristics
between curative adjuvant versus definitive (C)RT were performed
using the chi-square test to account for statistical differences. As
primary outcome parameter, OS was analyzed according to
intention to treat for patients with curative definitive or adjuvant
(C)RT and with palliative (C)RT. OS rates were analyzed by the
Kaplan–Meier method, and the log-rank test was used to assessFebruary 2021 | Volume 10 | Article 566318
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Cox proportional hazards models were used. Cut-off values for age
(area under the curve [AUC] 0.608, p = 0.005; 95% confidence
interval [CI] 0.535–0.681) and CCI (AUC 0.631, p = 0.001, 95% CI
0.558–0.703) were confirmed by receiver operating characteristic
(ROC) analysis at four years for death. The following
clinicopathological and treatment parameters were recorded and
analyzed: sex (male vs. female), age (≤75 vs. >75 years), CCI (<6 vs.
≥6), KPS (≥70 vs. <70%), T-classification (Tx/T1/T2 vs. T3/T4), N-
classification (negative vs. positive), UICC stage (I/II vs. III/IV),
tumor site (oropharynx vs. oral cavity vs. larynx vs. hypopharynx
vs. salivary glands vs. nasal/paranasal sinuses vs. nasopharynx vs.
CUP), histology, curative (C)RT (adjuvant vs. definitive), and
chemotherapy (no vs. yes). All survival-associated variables (p <
0.1) in the univariate analysis were further investigated using the
Cox multivariate regression model with stepwise backward logistic
regression. P values <0.05 were considered statistically significant.
Statistical analyses were performed using IBM SPSS Statistics,
Version 25.2 (IBM Corp., Armonk, NY, USA).RESULTS
Overall, 271 HNC patients aged ≥70 years fulfilled the criteria:
194 were male (71.6%) and 77 were female (28.4%). The median
age at diagnosis was 74 years (range, 70–92 years), and 111
patients (41.0%) were 76 years or older. Good KPS (100–70%)
was present in 178 patients (65.7%). CCI <6 was observed in 139
(51.3%) patients, and CCI ≥6 in 132 patients (48.7%). Tumor
stage T3/T4 and/or nodal positive stage was reported in 193
patients (71.2%). Distant metastases were observed in 15 patients
(5.5%). Advanced UICC stage III/IV was present in 245 patients
(90.4%). The majority of patients (95.6%) had squamous cell
carcinoma (SCC) (see Table 1).
In the curative setting (n = 231), 62 patients (43.1%) with
definitive and 21 (24.1%) with adjuvant (C)RT were older than
75 years, with the median age being 74 years (range, 70–92)
versus 73 years (range, 70–84 years, p = 0.398). Age categories
(years, definitive vs. adjuvant [C] RT) 70–75: 82 (56.9%) vs. 66
(75.9%), 76–80: 41 (28.5%) vs. 13 (14.9%), 81–85: 14 (9.7%) vs. 8
(9.2%), >85: 7 (4.9%) vs. 0 (0%) were significantly different (p =
0.009). Baseline characteristics for KPS, CCI, tumor site, N-
classification, and UICC stage were not significantly different in
HNC patients with definitive and adjuvant treatment intent. In
contrast, advanced T3/4-classification was significantly more
frequent for definitive treatment (115 patients, 79.9%) than for
adjuvant treatment (43 patients, 49.4%; p < 0.001).
Oropharyngeal cancer (OPC) was present in 35 (42.5%)
patients receiving adjuvant (C)RT and 52 (36.1%) receiving
definitive (C)RT. Although data on human papilloma virus
(HPV) status and smoking were not available for our patients,
a previous systematic survey on the trends in HPV prevalence
and smoking behavior at the Charité by our group revealed
persistently high rates of smokers in the OPC group and a slow
but continuous increase in the prevalence of HPV-driven low-
risk OPC (2004: 6%, 2013: 23%) (11). Curative treatment wasFrontiers in Oncology | www.frontiersin.org 3indicated in 231 patients (85.2%) and completed in 212 patients
(91.8%). Only 13 patients (9.0%) receiving definitive RT and six
patients (6.9%) receiving adjuvant RT did not finish treatment as
planned. In the curative setting, concurrent systemic therapy was
administered to 147 patients (63.6%), 110 patients (74.8%) had
definitive CRT, and 37 patients (25.2%) received adjuvant CRT.
Forty-one (47.1%) of the adjuvant therapy patients had
postoperative high-risk features, and in 90.2% of these cases,
concurrent CRT was scheduled. Cisplatin or mitomycin C ± 5-
fluorouracil was used in 51 (46.4%) and 45 patients (40.9%) in
the definitive treatment, respectively. Adjuvant CRT with
concurrent cisplatin was administered to 20 patients (54.1%).
Other drugs were administered to 31 (21.1%) of the curative
patients (Table 1).
In the palliative treatment intent group (n = 40), 25 patients
(62.5%) were 76 years or older, 29 (72.5%) had a CCI ≥6, and 32
patients (80%) had a KPS <70%. Thirty-six patients (90%) had a
UICC Stage IV, and 11 patients (27.5%) suffered from distant
metastasis from HNC. Nine patients (22.5%) received a total RT
dose of less than 20 Gy. Palliative concurrent CRT was
administered to 12 patients (30%). Mitomycin C was
administered to 11 patients (91.7%) and cetuximab to one
patient (8.3%).
In general, the majority of all patients (91.1%) had modern
RT treatment. A total of 175 patients underwent volumetric
modulated arc therapy (VMAT, 64.6%) and 72 patients received
intensity-modulated radiotherapy (IMRT, 26.6%), and 30.3% of
patients were treated with a simultaneous integrated boost (SIB).
Detailed patient, tumor, and treatment characteristics are
shown in Table 1.
Treatment Outcome
Curative Treatment
The median follow-up for survivors was 87 months (95% CI,
79.09–94.91, range 0–175) with 2- and 5-year OS rates of 57.8
and 35.9%, respectively. The median OS was 35 months (95% CI,
27.36–42.65) (see Figure 1A). The median OS was 46 vs. 23
months for age ≤75 vs. >75 years (95% CI, 29.97–62.03 vs. 8.93–
37.08, p < 0.001), 44 vs. 27 months for a CCI <6 vs. ≥6 (95% CI,
27.43–60.57 vs. 15.52–38.48, p= 0.001), 44 vs. 10 months with a
KPS ≥70 vs. <70% (95% CI, 33.66–54.34 vs. 3.39–16.61, p <
0.001), 52 vs. 27 months with Tx/T1/T2 vs. T3/T4 classification
(95% CI, 36.38–67.62 vs. 20.00–34.00, p = 0.036), and 52 vs. 23
months with adjuvant vs. definitive (C)RT (95% CI, 34.05–69.96
vs. 14.86–1.14, p = 0.003).
No significant differences were observed in terms of median
OS for sex (34 vs. 40 months, male vs. female, 95% CI, 25.13–
42.87 vs. 16.67–3.33, p = 0.2), N-negative vs.N-positive (36 vs. 34
months, 95% CI, 16.54–55.46 vs. 25.23–42.77, p = 0.921), and
UICC stage I/II vs. III/IV (36 vs. 34 months, 95% CI, 29.84–42.16
vs. 25.17–42.83, p = 0.971), and curative CRT vs. RT (42 vs. 28
months, 95% CI, 32.41–51.59 vs. 16.25–39.75, p = 0.528).
Moreover, the median OS was not different with definitive
CRT vs. definitive RT alone, but showed a trend towards
improved OS by CRT (25 compared to 13 months, 95% CI,
13.32–36.68 vs. 0–30.92, p = 0.085).February 2021 | Volume 10 | Article 566318
Stromberger et al. Radiotherapy for Older HNC PatientsTABLE 1 | Characteristics of older patients with head and neck cancer (n = 271).
Variable n = 271 (%)
Mean age at diagnosis of HNC, years (SD, range) 75.55 (5.113, 70–92)




Sex male 194 (71.6)





















Tumor site Oropharynx 98 (36.2)
Oral cavity 73 (26.9)
Larynx 39 (14.4)
Hypopharynx 29 (10.7)
Salivary glands 14 (5.2)
Nasal/paranasal sinus 11 (4.1)
Nasopharynx 4 (1.5)
CUP 3 (1.1)















N+ (not specified) 3 (1.1)
M-classification Positive 15 (5.5)





Histology SCC 259 (95.6)
Adeno cacinoma 5 (1.8)
Adenoid cystic carcinoma 3 (1.1)
other 4 (1.5)
Resection margin R0 41 (47.1)
R1, or close <5mm 18 (20.7)
(Continued)Frontiers in Oncology | www.frontiersin.org February 2021 | Volum4 e 10 | Article 566318
Stromberger et al. Radiotherapy for Older HNC PatientsThe 2-year OS rates were 64.1 vs. 46.6% for patients aged ≤75 vs.
>75 years, 63.8 vs. 50.8% with a CCI <6 vs. ≥6, 65.9 vs. 35.1% with a
KPS ≥70 vs. <70%, and 72.4 vs. 48.8% with adjuvant vs. definitive
RT, respectively. The 5-year OS rates were 43.1 vs. 23.3% aged ≤75
vs. >75 years, 43.2 vs. 27.1%with a CCI <6 vs. ≥6, 41.0 vs. 21.7%with
a KPS ≥70 vs. <70%, and 44.3 vs. 30.8% adjuvant vs. definitive (C)
RT, respectively (Figures 2A–D). Results of the univariate and
multivariate Cox regression analyses are shown in Table 2.Frontiers in Oncology | www.frontiersin.org 5Palliative Treatment
In patients with palliative treatment intent (n = 40), the
estimated median OS was four months (95% CI, 0.39–7.61,
Figure 1B). OS rates were not different for age groups [hazard
ratio (HR) 1.30, 95% CI, 0.65–2.61, p = 0.460], CCI (HR 1.37,
95% CI, 0.66–.84, p = 0.400), KPS (HR 1.65, 95% CI, 0.75–2.66,
p = 0.212), or application of chemotherapy (HR 0.62, 95% CI,
0.31–1.27, p = 0.189).TABLE 1 | Continued
Variable n = 271 (%)
ENE 17 (19.5)
R1 & ENE 6 (6.9)
missing 5 (5.7)
Therapy
Radiotherapy Definitive 144 (53.1)
completed 131 (91.0)
Mean dose, Gy (SD, range) 66.37 (12.957, 0-74.4)
Median dose, Gy 70.4
Adjuvant 87 (32.1)
completed 81 (93.1)
Mean dose, Gy (SD, range) 59.20 (9.928, 6-70.5)
Median dose, Gy 63.70
Palliative 40 (14.8)
completed 31 (77.4)
Mean dose, Gy (SD, range) 34.62 (13.135, 9-50)
Median dose, Gy 42.00
Systemic therapy 159 (58.7)
Cisplatin ± 5-FU 71 (44.7)




Drug unknown 1 (0.6)
Radiotherapy technique VMAT/IMRT 247 (91.1)
SIB 82 (30.3)
3D-CRT/2D-RT 24 (8.9)February 2021 | VolumHNC, head and neck cancer; SD, standard deviation; CUP, cancer of unknown primary; UICC, Union for International Cancer Control; SCC, squamous cell carcinoma; R, resection margin;
ENE, extracapsular extension; 5-FU, 5-flurouracil; TPF, taxan, platinum, 5-flurouracil; VMRT, volumetric modulated arc therapy; IMRT, intensity modulated radiotherapy; SIB, simultaneous
integrated boost; 3D-CRT, 3 conformal radiotherapy; 2D-RT 2 two-dimensional radiotherapy.A B
FIGURE 1 | | Kaplan–Meier curves of older patients with head and neck cancer (A) curative (B) palliative (chemo) radiation with respect to overall survival.e 10 | Article 566318
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Curative Treatment
Severe acute toxicity was observed as follows: mucositis grade
(G) 3 in 27 (11.7%) and G4 in two (0.9%), dermatitis G3 in 23
(10%), dysphagia G3 and G4 in 87 (37.7%), and two (0.9%), dry
mouth G3 in two (0.9%), fatigue G3 in one (0.4%), nausea G3 in
one (0.4%), and pain G3 in 12 (5.2%) patients. Sepsis,
pneumonia, and peritonitis were reported in five (2.2%) and 12
(5.2%) and three (1.3%) patients, respectively. All of these
patients had definitive R(C)T. Two patients (0.9%) had a
thrombosis, and one (0.4%) had an embolic lung event. Six
patients (2.6%) died during the first 30 days of treatment (days
4–30), one from pneumonia, one from peritonitis, one from
embolic lung event and bleeding, three (1.2%) deaths were due to
tumor (progressive disease) and not treatment-related. In
summary, three (1.2%) elderly patients died during the first 30
days of treatment.
Palliative Treatment
Acute toxicity G3 with mucositis was observed in three patients
(7.5%), dysphagia in 16 (40%), dry mouth (2.5%), nauseaFrontiers in Oncology | www.frontiersin.org 6(2.5%), and pain (12.5%). Two patients had sepsis (5%), one
(2.5%) thrombosis, six patients (15%) had pneumonia, and
one patient (2.5%) had peritonitis. Six patients (15%) died
within 20 days of treatment (range, 6–17 days), one (2.5%)
from sepsis, one (2.5%) from peritonitis, and four patients (10%)
due to progressive disease and/or progressive weakness
and deterioration.DISCUSSION
This study assessed the OS of older patients with HNC treated
with curative and palliative (C)RT with respect to comorbidities
and performance scores in baseline assessments. Age has been
investigated in previous studies of cancer (12, 13). In HNC
patients with a mean age of 60 years, age was found to be a
significant risk factor for non-cancer-related death, with an
estimated HR of 1.05 per year (14). In a Japanese study, the
risk of non-cancer-related death increased with an HR of 2.59 in
patients aged 76 years and older, without a significant increase in
HNC-related deaths (13). Kwon et al. reported a rate of 9.2%A B
C D
FIGURE 2 | | Kaplan–Meier curves of older patients with head and neck cancer and curative (chemo) radiation (A) age ≤75 vs. >75 years (B) CCI <6 vs. ≥6 points
(C) KPS ≥70 vs. <70% (D) adjuvant vs. definitive (chemo) radiation with respect to overall survival.February 2021 | Volume 10 | Article 566318
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treated HNC patients, with respiratory events being the leading
cause of death (12).
Our treatment recommendation elaborated in an interdisciplinary
tumor board for each older patient was based on national and
international treatment guidelines. Considering competing risks
as a cause of death, older age (>75 years) before curative (C)RT
was found to be a significant risk factor for survival in the
univariate and multivariate analyses (HR 1.82, p > 0.001; HR
1.61, p = 0.004). Patients aged 70–75 years compared to 76 years
or older had a gain of 23 months in median OS, and superior 2-
year survival rates of 64.1 versus 46.6%. A recent retrospective
German study on HNC patients with a median age of 72 years
found a median OS of 40 vs. 22 months (p < 0.05) for patientsFrontiers in Oncology | www.frontiersin.org 7aged 65–74 years and ≥ 75 years, but the age factor was not
significant in the multivariate analysis (15).
To date, older patients aged ≥70 years with LA HNC have
not been the primary candidates for treatment intensification
in prospective clinical trials aiming at survival improvement
because an increase in toxicities is a major concern with more
aggressive treatment schedules (16). Moreover, treatment de-
intensification with less toxic strategies while maintaining
good oncological results has been the approach in recent
years, e.g., in HPV-positive oropharyngeal cancer patients of
all ages and in dedicated studies for older patients with HNC
(17–20). A meta-analysis showed that the survival benefit of
standard concurrent chemoradiation in HNC patients aged 71
years or older significantly decreases with age, and the effect ofTABLE 2 | | Univariate and multivariate analysis of clinicopathological and treatment parameters associated with overall survival (OS) in older patients with HNC and
curative intended (chemo) radiation.
Univariate Analysis
Variable N = 231 HR 95% CI p-value
Sex Male 168 0.799 0.565–1.131 0.204
Female 63
Age (years) ≤75 148 1.822 1.332–2.493 0.000
>75 83
CCI <6 128 1.662 1.225–2.254 0.001
≥6 103
KPS ≥70% 170 1.921 1.373–2.687 0.000
<70% 61
T-classification Tx/T1/T2 73 1.422 1.018–1.986 0.035
T3/T4 158
N-classification negative 67 0.984 0.706–1.370 0.922
positive 164
UICC stage 7th I/II 24 0.991 0.607–1.618 0.971
III/IV 205








RT treatment adjuvant 87 1.614 1.170–2.225 0.004
definitive 144
Chemotherapy No 84 1.106 0.806–1.519 0.532
Yes 147
Multivariate Analysis
Variable N = 231 HR 95% CI p-value
Age (years) ≤75 148 1.606 1.167–2.212 0.004
>75 83
CCI <6 128 1.470 1.080–2.001 0.014
≥6 103
KPS ≥70% 170 1.896 1.342–2.679 0.001
<70% 61
T-classification Tx/T1/T2 74 1.133 0.792–1.620 0.492
T3/T4 157
RT treatment adjuvant 87 1.560 1.118–2.176 0.008
definitive 144February 2021 | Volume 10 | ArticleHNC, head and neck cancer; HR, hazard ratio, 95% CI, 95% confidence interval; CCI, Charlson Comorbidity Index; KPS, Karnofsky performance status; CUP, cancer of unknown primary;
RT, radiotherapy.566318
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mono-chemotherapy with cisplatin (5). We focused on HNC
patients aged 70 years and older, with LA UICC stage and
observed, in line with the data of Pignon et al. (5), that the
addition of systemic therapy to curative definitive RT at this
age had no additional effect on survival. However, our data
need to be interpreted with caution since only 24% underwent
radiotherapy alone. Up to 44% of patients had concurrent
polychemotherapy with a potential effect on toxicity. We observed
higher rates of severe acute toxicity such as dysphagia (44.4 vs.
28.7%) and dermatitis (12.5 vs. 5.8%) in the definitive (C)RT
group, where 76% had simultaneous chemotherapy compared to
patients in the adjuvant setting, with only approximately 43%
receiving concurrent CRT.
A review on the management of older patients with locally
advanced HNC suggests that, in addition to chronological age,
the biological phenotype should be considered as a guide for
the best treatment approach in terms of aggressiveness and
likelihood of tolerance in terms of oncologic outcome and
limitation of side effects (21). Frailty is defined as a reduced
resistance or reserve to stressors, which leads to an increased
risk of falls, disability, hospitalization, and death (22). Frail
older patients with HNC should be treated aiming at symptom
control through palliative RT or palliative care (21). As the
majority of patients were aged 76 years or older, 80% had a
reduced KPS and multiple comorbidities (CCI >6) in 72.5%,
we observed a limited survival time of an estimated median 4
months after palliative RT with a mean dose of 34.6 Gy.
Unfortunately, nine patients (22.5%) developed severe
infections and six patients (15%) died within the first 17
days of palliative RT, while in the curative group, only 1.2%
of older patients died within the first 30 days. Moreover,
almost half of our palliative patients (40%) still had severe
swallowing problems. This suggests that the selection of
patients for palliative radiotherapy is crucial, and best
supportive care needs to be considered a valid option for
palliation. Lin et al. reported a 6.66% rate of 90-day mortality
for patients with HNC at any age after the completion of
definitive concurrent CRT. In addition to other factors,
patients aged >70 years had a significantly increased risk of
death (HR 2.18; 95% CI, 1.80-2.65; p < 0.001) within 90 days
after treatment (3). This 90-day mortality scoring system
might be suitable for finding and selecting older patients
who would benefit from a more conservative treatment than
concurrent CRT (3). However, identifying the fit, moderate fit,
and frail older patients remains challenging. By applying CGA
in cancer patients aged 70 years or older, a Danish study group
found that up to 87% of patients with cancer types often seen
in older patients and often connected to comorbidity were
either vulnerable or frail. Patients with lung cancer, colorectal
cancer, or gastrointestinal cancer and 14.6% of HNC patients were
included in this study (23). The utility of CGA for older patients
with HNC is currently under evaluation in ongoing trials such as
GEROP (NCT03053310) or ELAN-ONCOVAL (NCT03614936).
Recently, an estimated mean time frame of 51 minutes per patient
with an additional 5–10min for calculating the scores has beenFrontiers in Oncology | www.frontiersin.org 8described for a CGA (23). CGA was not performed in our study. As
a baseline evaluation, we assessed the pre-radiotherapeutic patients’
performance status and comorbidities to estimate fitness,
vulnerability, or frailty of the patient, and integrated these factors
into the decision-making. For cancer outcome at any patient age,
the performance status has been shown to be of prognostic
significance (15, 24). Consistent with the literature, we found in
our curative cohort that a reduced KPS of 60% or less resulted in
decreased survival. A low KPS was particularly often present in our
palliative cohort.
Beyond age and KPS, the presence of multiple comorbidities, in
our study reflected by the CCI ≥6, showed a significant
negative prognostic influence on OS with curative (C)RT in
univariate and multivariate analyses. In a large Surveillance,
Epidemiology, and End Results (SEER)-Medicare linked
database study on older patients with HNC, a high prevalence
of comorbidities such as hypertension, hyperlipidemia, chronic
obstructive pulmonary disease, and diabetes at the time of
diagnosis, and an increased likelihood of developing cancer-
related comorbidities such as dysphagia, weight loss, or
pneumonia after treatment was observed (25). Both findings
are associated with a significantly increased risk of death in
HNC patients at any age (26). Ryu and colleagues showed that
comorbidities may compete for non-cancer risk factors in
patients with HNSCC (27). Furthermore, comorbidities
(14%), treatment-related acute (9%), and late toxicity (3%)
accounted for 5-year non-cancer-related death rates of 4.1,
4.6, and 1.3%, respectively, in patients with LA HNC treated
with CRT (14). Although acute toxicity was already high in our
study, with the most common treatment-related side effects
≥ G3 being dysphagia in approximately 39%, 13% mucositis,
and 11% dermatitis in curative patients, an underestimation of
side effects needs to be assumed due to the retrospective nature
of this study.
In our study, the curative treatment of choice was mostly
definitive (C)RT, with 105 patients in UICC IV stage (72.9%),
and the minority had surgery with adjuvant (C)RT. The adjuvant
treated patients were significantly less likely to have an advanced
T3/T4 stage and only 24.1% of the patients were older than 75
years. Furthermore, only approximately one-third (33%) of the
adjuvant compared to two-thirds (67%) of the definitive treated
patients presented with a CCI ≥6. All these factors might have
favored the decision for surgery in older patients with less
comorbidities. Perhaps, multimodal treatment with surgery
independently predicted better survival than definitive RT. For
older patients with oropharyngeal cancer, a SEER-Medicare data
analysis found no difference in survival between surgery and
definitive RCT (28). Recently, Yoshida and colleagues published
data from the National Cancer Data Base on a large cohort of
curative resected HNC patients aged 70 years or older with high-
risk features (ENE and/or positive margin) treated with
postoperative RT or CRT. Patients older than 74 years were
significantly less frequently treated with CRT. They found 3-year
OS rates of 52.4% in favor of concurrent CRT (p = 0.012) and an
approximately 25% decreased risk of death through CRT vs. RT,
especially with N2-N3 nodal involvement but not in nodalFebruary 2021 | Volume 10 | Article 566318
Stromberger et al. Radiotherapy for Older HNC Patientsnegative disease. Performance status, comorbidities, or side-
effects were not investigated in the study (29).
Multiple limitations of our study need to be mentioned. In
particular, the retrospective nature led to differences in the
baseline characteristics of the patients in the definitive and
postoperative (C)RT cohorts, which might have introduced a
selection bias suggesting improved outcome with adjuvant
treatment. Characteristics such as smoking history and the
HPV, nutritional, or functional status were not available.
Nevertheless, data from a previous study of the group on the
prevalence of HPV and smoking habits suggest a relatively
small proportion of HPV-associated low-risk OPC cases within
our cohort (11). Furthermore, in the palliative setting, the
relatively small number of patients also limited the validity of
the analysis. A CGA or even an additional quick further
performance measurement, such as using the timed “up and
go” test (stand up from sitting, walk 3 m and return in less than
12 s), a useful tool that could have been easily integrated in the
daily routine, was not performed (30). An analysis of loco-
regional control, distant metastasis, or second cancer was not
performed. We would like to emphasize the urgent need for
prospective studies including geriatric assessment.
In summary, treatment for older patients with locally advanced
HNC cancer remains a challenge, andmultiple factors may influence
survival. Older patients with HNC may benefit from curative more
or less intense (C)RT with good compliance and decent survival;
however, caution is advised in patients with advanced old age,
reduced KPS, and multiple comorbidities. Frailty patients treated
with radiotherapy have limited survival and symptom control.
Prospective studies are awaited, but simple assessments could by
now help to guide clinical decision-making.Frontiers in Oncology | www.frontiersin.org 9DATA AVAILABILITY STATEMENT
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